<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-99177</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Natural history and outcome in systemic AA amyloidosis</dc:title>
<dc:creator>Goodman, H. J</dc:creator>
<dc:creator>Ortiz-Herbener, F</dc:creator>
<dc:creator>Sabin, C. A</dc:creator>
<dc:creator>Lachmann, H. J</dc:creator>
<dc:creator>Gilbertson, J. A</dc:creator>
<dc:creator>Hawkins, P. N</dc:creator>
<dc:creator>Gillmore, J. D</dc:creator>
<dc:creator>Barrio, V</dc:creator>
<dc:creator>Gallimore, J. R</dc:creator>
<dc:language>es</dc:language>
<dc:source>Nefrologia;28(supl.2): 8-9, ene.-dic. 2008. ilus</dc:source>
<dc:identifier>ibc-99177</dc:identifier>
<dc:title xml:lang="es">¿Mejora el pronóstico de la amiloidosis sistémica el tratamiento para controlar la actividad de la enfermedad inflamatoria subyacente y reducir la concentración sérica de la proteína AA?</dc:title>
<dc:subject>^d699^s22057</dc:subject>
<dc:subject>^d29625</dc:subject>
<dc:subject>^d54061^s22062</dc:subject>
<dc:subject>^d50495^s22032</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d7426^s22057</dc:subject>
<dc:subject>^d32285</dc:subject>
<dc:type>article</dc:type>
<dc:date>200812</dc:date>
</metadata>
</record>
</ibecs-document>
